Clear Search sequence regions


  • antigens (2)
  • autoantibodies (1)
  • autoantigen (1)
  • b lymphocytes (1)
  • cancer (1)
  • CRMP5 (11)
  • CV2 (10)
  • dorsal root ganglia (2)
  • lung (1)
  • nervous system (1)
  • neuron (3)
  • nociceptor (1)
  • patients (5)
  • rats (2)
  • rodent (1)
  • spinal cord (1)
  • thymoma (1)
  • Sizes of these terms reflect their relevance to your search.

    Paraneoplastic neurological syndromes arise from autoimmune reactions against nervous system antigens due to a maladaptive immune response to a peripheral cancer. Patients with small cell lung carcinoma or malignant thymoma can develop an autoimmune response against the CV2/collapsin response mediator protein 5 (CRMP5) antigen. For reasons that are not understood, approximately 80% of patients experience painful neuropathies. Here, we investigated the mechanisms underlying anti-CV2/CRMP5 autoantibodies (CV2/CRMP5-Abs)-related pain. We found that patient-derived CV2/CRMP5-Abs can bind to their target in rodent dorsal root ganglia (DRG) and superficial laminae of the spinal cord. CV2/CRMP5-Abs induced DRG neuron hyperexcitability and mechanical hypersensitivity in rats that were abolished by preventing binding to their cognate autoantigen CRMP5. The effect of CV2/CRMP5-Abs on sensory neuron hyperexcitability and mechanical hypersensitivity observed in patients was recapitulated in rats using genetic immunization providing an approach to rapidly identify possible therapeutic choices for treating autoantibody-induced pain including the repurposing of a monoclonal anti-CD20 antibody that selectively deplete B-lymphocytes. These data reveal a previously unknown neuronal mechanism of neuropathic pain in patients with paraneoplastic neurological syndromes resulting directly from CV2/CRMP5-Abs-induced nociceptor excitability. CV2/CRMP5-Abs directly sensitize pain responses by increasing sensory neuron excitability and strategies aiming at either blocking or reducing CV2/CRMP5-Abs can treat pain as a comorbidity in patients with paraneoplastic neurological syndromes.

    Citation

    Laurent Martin, Harrison J Stratton, Kimberly Gomez, Do Le Duy, Santiago Loya-Lopez, Cheng Tang, Aida Calderon-Rivera, Dongzhi Ran, Venkatrao Nunna, Shreya S Bellampalli, Liberty François-Moutal, Nicolas Dumaire, Lyuba Salih, Shizhen Luo, Frank Porreca, Mohab Ibrahim, Véronique Rogemond, Jérôme Honnorat, Rajesh Khanna, Aubin Moutal. Mechanism, and treatment of anti-CV2/CRMP5 autoimmune pain. bioRxiv : the preprint server for biology. 2024 May 07


    PMID: 38766071

    View Full Text